Type D retrovirus capsid assembly and release are active events requiring ATP

Journal of Virology

Volumn 72, Issue 4, 1998, Pages 3098-3106

  Weldon Jr , Robert A ^a   Parker, William B ^b   Sakalian, Michael ^a   Hunter, Eric ^a,c  

^a University of Alabama at Birmingham   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

^c 256 BBRB ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CAPSID PROTEIN; CELL PROTEIN; GAG PROTEIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; HELA CELL; HUMAN; HUMAN CELL; MASON PFIZER MONKEY VIRUS; MONKEY; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; VIRUS ASSEMBLY; VIRUS CAPSID; VIRUS ENVELOPE; VIRUS MORPHOLOGY; VIRUS STRAIN;

EID: 2642608675     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.4.3098-3106.1998     Document Type: Article

References (61)

1. Ahmed, M., S. A. Mayyasi, H. C. Chopra, I. Zelljadt, and E. M. Jensen. 1971. Mason-Pfizer monkey virus isolated from spontaneous mammary carcinoma of a female monkey. I. Detection of virus antigens by immunodiffusion, immunofluorescent, and virus agglutination techniques. J. Natl. Cancer Inst. 46:1325-1334.
2. Arthur, L. O., J. Bess, Jr., R. C. Sowder II, R. E. Benveniste, D. L. Mann, J. C. Chermann, and L. E. Henderson. 1992. Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science 258:1935-1938.
3. Bennett, R. P., T. D. Nelle, and J. W. Wills. 1993. Functional chimeras of the Rous sarcoma virus and human immunodeficiency virus Gag proteins. J. Virol. 67:6487-6498.
4. Campbell, S., and V. M. Vogt. 1995. Self-assembly in vitro of purified CA-NC proteins from Rous sarcoma virus and human immunodeficiency virus type 1. J. Virol. 69:6487-6497.
5. Campbell, S., and V. M. Vogt. 1997. In vitro assembly of virus-like particles with Rous sarcoma virus Gag deletion mutants: identification of the p10 domain as a morphological determinant in the formation of spherical particles. J. Virol. 71:4425-4435.
6. Chopra, H. C., and M. M. Mason. 1970. A new virus in a spontaneous mammary tumor of a rhesus monkey. Cancer Res. 30:2081-2086.
7. Christensen, A. M., M. A. Massiah, B. G. Turner, W. I. Sundquist, and M. F. Summers. 1996. Three-dimensional structure of the HTLV-II matrix protein and comparative analysis of matrix proteins from the different classes of pathogenic human retroviruses. J. Mol. Biol. 264:1117-1131.
8. Conte, M. R., M. Klikova, E. Hunter, T. Ruml, and S. Matthews. 1997. The three-dimensional solution structure of the matrix protein from the type D retrovirus, the Mason-Pfizer monkey virus. EMBO J. 16:5819-5826.
9. Deminie, C. A., and M. Emerman. 1993. Incorporation of human immunodeficiency virus type 1 Gag proteins into murine leukemia virus virions. J. Virol. 67:6499-6506.
10. Deminie, C. A., and M. Emerman. 1994. Functional exchange of an oncoretrovirus and a lentivirus matrix protein. J. Virol. 68:4442-4449.
11. gag and retrovirus assembly. Virology 130:415-426.
12. gag and assembly of retrovirus temperature-sensitive mutants in chronically infected cells. Virology 134:389-397.
13. Eisenman, R. N., V. M. Vogt, and H. Diggelmann. 1974. Synthesis of avian RNA tumor virus structural proteins. Cold Spring Harbor Symp. Quant. Biol. 39:1067-1075.
14. Frydman, J., E. Nimmesgern, H. Erdjument-Btomage, J. S. Wall, P. Tempst, and F. Hartl. 1992. Function in protein folding of TRiC, a cytosolic ring complex containing TCP-1 and structurally related subunits. EMBO J. 11: 4767-4778.
15. Göttlinger, H. G., J. G. Sodroski, and W. A. Haseltine. 1989. Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type I. Proc. Natl. Acad. Sci. USA 86:5781-5785.
16. Hartl, F. U. 1996. Molecular chaperones in cellular protein folding. Nature 381:571-579.
17. Henderson, L. E., H. C. Krutzsch, and S. Oroszlan. 1983. Myristyl aminoterminal acylation of murine retrovirus proteins: an unusual post-translational protein modification. Proc. Natl. Acad. Sci. USA 80:339-443.
18. Hill, C. P., D. Worthylake, D. P. Bancroft, A. M. Christensen, and W. I. Sundquist. 1996. Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: implications for membrane association and assembly. Proc. Natl. Acad. Sci. USA 93:3099-3104.
19. Hunter, E. 1994. Macromolecular interactions in the assembly of HIV and other retroviruses. Semin. Virol. 5:71-83.
20. Hunter, E., and R. Swanstrom. 1990. Retrovirus envelope glycoproteins. Curr. Top. Microbiol. Immunol. 157:187-254.
21. Klikova, M., S. S. Rhee, E. Hunter, and T. Ruml. 1995. Efficient in vivo and in vitro assembly of retroviral capsids from Gag precursor proteins expressed in bacteria. J. Virol. 69:1093-1098.
22. Leis, J., D. Baltimore, J. M. Bishop, J. Coffin, E. Fleissner, S. P. Goff, S. Oroszlan, H. Robinson, A. M. Skalka, H. M. Temin, and V. Vogt. 1988. Standardized and simplified nomenclature for proteins common to all retroviruses. J. Virol. 62:1808-1809.
23. Lingappa, J. R., R. L. Hill, M. L. Wong, and R. S. Hegde. 1997. A multistep, ATP-dependent pathway for assembly of human immunodeficiency virus capsids in a cell-free system. J. Cell Biol. 136:567-581.
24. Lingappa, J. R., R. L. Martin, M. L. Wong, D. Ganem, W. J. Welch, and V. R. Lingappa. 1994. A eukaryotic cytosolic chaperonin is associated with a high molecular weight intermediate in the assembly of hepatitis B virus capsid, a multimeric particle. J. Cell Biol. 125:99-111.
25. MacDonald, H. R., and C. J. Kock. 1977. Energy metabolism and T-cell-mediated cytolysis. J. Exp. Med. 146:698-709.
26. Maldarelli, F., N. W. King, Jr., and M. J. Yagi. 1987. Effects of cytoskeletal disrupting agents on mouse mammary tumor virus replication. Virus Res. 7:281-295.
27. Massiah, M. A., M. R. Starich, C. Paschall, M. F. Summers, A. M. Christensen, and W. I. Sundquist. 1994. Three-dimensional structure of the human immunodeficiency virus type 1 matrix protein. J. Mol. Biol. 244:198-223.
28. Matthews, S., P. Barlow, J. Boyd, G. Barton, R. Russell, H. Mills, M. Cunningham, N. Meyers, N. Burns, N. Clark, S. Kingsman, A. Kingsman, and I. Campbell. 1994. Structural similarity between the p17 matrix protein of HIV-1 and interferon-gamma. Nature 370:666-668.
29. Matthews, S., P. Barlow, N. Clark, S. Kingsman, A. Kingsman, and I. Campbell. 1995. Refined solution structure of p17, the HIV matrix protein. Biochem. Soc. Trans. 23:725-729.
30. Matthews, S., M. Mikhailov, A. Burny, and P. Roy. 1996. The solution structure of the bovine leukemia virus matrix protein and similarity with lentiviral matrix proteins. EMBO J. 15:3267-3274.
31. Nelle, T. D., and J. W. Wills. 1996. A large region within the Rous sarcoma virus matrix protein is dispensable for budding and infectivity. J. Virol. 70:2269-2276.
32. Ott, D. E., L. V. Coren, B. P. Kane, L. K. Busch, D. G. Johnson, R. C. Sowder II, E. N. Chertova, L. O. Arthur, and L. E. Henderson. 1996. Cytoskeletal proteins inside human immunodeficiency virus type 1 virions. J. Virol. 70: 7734-7743.
33. Panem, S. 1977. Cell cycle-dependent inhibition of Kirsten murine sarcoma-leukemia virus release by cytochalasin B. Virology 76:146-151.
34. Parent, L. J., R. P. Bennett, R. C. Craven, T. D. Nelle, N. K. Krishna, J. B. Bowzard, C. B. Wilson, B. A. Puffer, R. C. Montelaro, and J. W. Wills. 1995. Positionally independent and exchangeable late budding functions of the Rous sarcoma virus and human immunodeficiency virus Gag proteins. J. Virol. 69:5455-5460.
35. Parker, W. B., S. C. Shaddix, C. H. Chang, E. L. White, L. M. Rose, R. W. Brockman, A. T. Shortnacy, J. A. Montgomery, J. Secrist, and L. Bennett, Jr. 1991. Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res. 51:2386-2394.
36. Purchio, A. F., S. Jovanovich, and R. L. Erikson. 1980. Sites of synthesis of viral proteins in avian sarcoma virus-infected chicken cells. J. Virol. 35:629-636.
37. Rao, Z., A. S. Belyaev, E. Fry, P. Roy, I. M. Jones, and D. I. Stuart. 1995. Crystal structure of SIV matrix antigen and implications for virus assembly. Nature 378:743-747.
38. Rey, O., J. Canon, and P. Krogstad. 1996. HIV-1 Gag protein associates with F-actin present in microfilaments. Virology 220:530-534.
39. Rhee, S. S., and E. Hunter. Unpublished results.
40. Rhee, S. S., and E. Hunter. 1987. Myristylation is required for intracellular transport but not for assembly of D-type retrovirus capsids. J. Virol. 61:1045-1053.
41. Rhee, S. S., and E. Hunter. 1990. A single amino acid substitution within the matrix protein of a type D retrovirus converts its morphogenesis to that of a type C retrovirus. Cell 63:77-86.
42. Rhee, S. S., and E. Hunter. 1990. Structural role of the matrix protein of type D retroviruses in Gag polyprotein stability and capsid assembly. J. Virol. 64:4383-4389.
43. Rhee, S. S., and E. Hunter. 1991. Amino acid substitutions within the matrix protein of type D retroviruses affect assembly, transport, and membrane-association of a capsid. EMBO J. 10:535-546.
44. Sakalian, M., S. D. Parker, R. A. Weldon, Jr., and E. Hunter. 1996. Synthesis and assembly of retrovirus gag precursors into immature capsids in vitro. J. Virol. 70:3706-3715.
45. Sasaki, H., M. Nakamura, T. Ohno, Y. Matsuda, Y. Yuda, and Y. Nonomura. 1995. Myosin-actin interaction plays an important role in human immunodeficiency virus type 1 release from host cells. Proc. Natl. Acad. Sci. USA 92:2026-2030.
46. Satake, M., and R. B. Loftig. 1982. Microtubule-depolymerizing agents inhibit Moloney leukemia virus production. J. Gen. Virol. 58:339-349.
47. Schultz, A., L. E. Henderson, and S. Oroszlan. 1988. Fatty acylation of proteins. Annu. Rev. Cell Biol. 4:611-647.
48. Schultz, A. M., E. H. Rabin, and S. Oroszlan. 1979. Post-translational modification of Rauscher leukemia virus precursor polyproteins encoded by the gag gene. J. Virol. 30:255-266.
49. gag is excluded from virus assembly and maturation events. J. Virol. 63:2370-2373.
50. Sommerfelt, M. A., S. S. Rhee, and E. Hunter. 1992. Importance of p12 protein in Mason-Pfizer monkey virus assembly and infectivity. J. Virol. 66:7005-7011.
51. Stewart, L., G. Schatz, and V. M. Vogt. 1990. Properties of avian retroviral particles defective in viral protease. J. Virol. 64:5076-5092.
52. Todd, M. J., P. V. Viitanen, and G. H. Lorimer. 1994. Dynamics of the chaperonin ATPase cycle: implications for facilitated protein folding. Science 265:659-666.
53. Trinchieri, G., and M. De Marchi. 1975. Antibody-dependent cell-mediated cytotoxicity in humans. II. Energy requirement. J. Immunol. 115:256-260.
54. Weldon, R. A., Jr., C. R. Erdie, M. G. Oliver, and J. W. Wills. 1990. Incorporation of chimeric Gag protein into retroviral particles. J. Virol. 64:4169-4179.
55. Weldon, R. A., Jr., and E. Hunter. 1996. Molecular requirements for retrovirus assembly, p. 381-410. In W. Chiu, R. M. Burnett, and R. L. Garcea (ed.), Structural biology of viruses. Oxford University Press, New York, N.Y.
56. Weldon, R. A., Jr., and J. W. Wills. 1993. Characterization of a small (25-kDa) derivative of the Rous sarcoma virus Gag protein competent for particle release. J. Virol. 67:5550-5561.
57. Wills, J. W., C. E. Cameron, C. B. Wilson, Y. Xiang, R. P. Bennett, and J. Leis. 1994. An assembly domain of the Rous sarcoma virus Gag protein required late in budding. J. Virol. 68:6605-6618.
58. Wills, J. W., and R. C. Craven. 1991. Form, function, and use of retroviral Gag proteins. AIDS 5:639-654.
59. Yasuda, J., and E. Hunter. A proline-rich motif (PPPY) in the Gag polyprotein of Mason-Pfizer monkey virus plays a maturation-independent role in virion release. J. Virol., in press.
60. Zhou, W., L. J. Parent, J. W. Wills, and M. D. Resh. 1994. Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids. J. Virol. 68:2556-2569.
61. Zhou, W., and M. D. Resh. 1996. Differential membrane binding of the human immunodeficiency virus type 1 matrix protein. J. Virol. 70:8540-8548.